Prognostic impact of Fas ligand on hepatocellular carcinoma after hepatectomy.
Lee
Wei-Chen
WC
Department of General Surgery, Chang-Gung Memorial Hospital, 5 Fu-Hsing Street, Kwei-Shan Hsiang, Taoyuan, Taiwan.
Yu
Ming-Chin
MC
Chen
Miin-Fu
MF
D000328:Adult; D000368:Aged; D017209:Apoptosis / Q000502:physiology; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000473:pathology* / Q000601:surgery*; D002471:Cell Transformation, Neoplastic / Q000473:pathology; D018572:Disease-Free Survival; D053222:Fas Ligand Protein; D005260:Female; D006498:Hepatectomy; D006801:Humans; D007124:Immunoenzyme Techniques; D008099:Liver / Q000473:pathology; D008113:Liver Neoplasms / Q000401:mortality / Q000473:pathology* / Q000601:surgery*; D008297:Male; D008562:Membrane Glycoproteins / Q000032:analysis*; D008875:Middle Aged; D011379:Prognosis; D013223:Statistics as Topic; D016019:Survival Analysis
C505661:FASLG protein, human; D053222:Fas Ligand Protein; D008562:Membrane Glycoproteins